MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/00365521.2025.2553284

Медицинская библиотека · Scandinavian journal of gastroenterology · 2025

Comparison of liver histology and fibrosis-4 scoring as tools for evaluating healthcare resource utilization and costs in patients with MASLD: a Swedish cohort study.

Toresson Grip Emilie, Kant Mangla Kamal, Ota Riku, Künkel Winther Marc, Shang Ying, Skröder Helena, Vessby Johan, Kechagias Stergios, Hagström Hannes

СтатьяНаблюдательное исследованиеСравнительное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with substantial clinical and economic burden. Fibrosis detection is key to disease management, but biopsy-defined staging is invasive, expensive, and associated with complications. We evaluated healthcare resource utilization (HCRU) and costs by disease stage using biopsy-defined staging and fibrosis-4 (FIB-4; a simple, well-validated, non-invasive tool for assessing fibrosis severity), and compared their utility for predicting long-term outcomes in MASLD.

METHODS

This longitudinal observational cohort study included 959 adults with biopsy‑defined MASLD in Swedish medical records (1974-2020) linked to national registers. Patients had a documented fibrosis stage (F0-F4) and age-stratified FIB-4 score (low, indeterminate, high) at baseline. All-cause, liver-, and cardiovascular (CV)-related HCRU/costs were evaluated. The predictive capacity of biopsy and FIB-4 for high HCRU (≥80th percentile of hospitalizations + outpatient visits) was assessed using Harrell's concordance index.

RESULTS

In general, patients with advanced fibrosis had significantly more all-cause and liver-related hospitalizations, longer length of stay, and higher costs than patients with less advanced fibrosis. The number and cost of liver-related outpatient visits increased significantly as fibrosis severity increased, a trend also observed when comparing high and low FIB-4 scores. Other HCRU/cost outcomes were inconsistent between scoring approaches. No association was found between CV-related HCRU and fibrosis severity. Biopsy and FIB-4 demonstrated similar predictive capacity for identifying patients with high HCRU.

CONCLUSIONS

These data highlight the positive association between fibrosis severity and HCRU and costs in MASLD, and suggest that FIB-4 may have similar utility to biopsy for evaluating certain HCRU outcomes.

Для цитирования: Toresson Grip Emilie, Kant Mangla Kamal, Ota Riku, Künkel Winther Marc, Shang Ying, Skröder Helena, Vessby Johan, Kechagias Stergios, Hagström Hannes. Comparison of liver histology and fibrosis-4 scoring as tools for evaluating healthcare resource utilization and costs in patients with MASLD: a Swedish cohort study.. Scandinavian journal of gastroenterology. 2025. DOI: 10.1080/00365521.2025.2553284.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.